We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: primary sclerosing cholangitis
MedXY News
EnglishTag

primary sclerosing cholangitis

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Beyond Pathology: DNA/RNA Sequencing Achieves Near-Double Sensitivity in Detecting Bile Duct Cancer
Gastroenterologybile duct stricturesCholangiocarcinoma

Beyond Pathology: DNA/RNA Sequencing Achieves Near-Double Sensitivity in Detecting Bile Duct Cancer

By MedXY|Apr 2, 2026

A landmark six-year study involving over 2,000 patients at 28 institutions demonstrates that next-generation sequencing of ERCP-obtained specimens achieves 82% sensitivity for neoplastic bile duct strictures, nearly doubling traditional pat

Cilofexor Did Not Prevent Fibrosis Progression in Non‑Cirrhotic Primary Sclerosing Cholangitis: Results from the PRIMIS Phase 3 Trial
Gastroenterologyclinical trialprimary sclerosing cholangitis

Cilofexor Did Not Prevent Fibrosis Progression in Non‑Cirrhotic Primary Sclerosing Cholangitis: Results from the PRIMIS Phase 3 Trial

By MedXY|Nov 8, 2025

The phase 3 PRIMIS trial found cilofexor 100 mg once daily did not reduce histological fibrosis progression at 96 weeks in non‑cirrhotic primary sclerosing cholangitis; pruritus was more frequent with cilofexor.

Elafibranor Shows Promise as a Safe and Effective Therapy for Primary Sclerosing Cholangitis: Insights from the Phase II ELMWOOD Trial
Gastroenterologyliver diseaseprimary sclerosing cholangitis

Elafibranor Shows Promise as a Safe and Effective Therapy for Primary Sclerosing Cholangitis: Insights from the Phase II ELMWOOD Trial

By MedXY|Oct 29, 2025

The phase II ELMWOOD trial demonstrates that elafibranor, a dual PPAR-α/δ agonist, is well tolerated and significantly improves biochemical markers in patients with primary sclerosing cholangitis over 12 weeks, warranting further investigat

Bexotegrast in Primary Sclerosing Cholangitis: Promising Safety and Pharmacodynamics from Phase II INTEGRIS-PSC Trial
GastroenterologyBexotegrastliver fibrosis

Bexotegrast in Primary Sclerosing Cholangitis: Promising Safety and Pharmacodynamics from Phase II INTEGRIS-PSC Trial

By MedXY|Oct 28, 2025

The Phase II INTEGRIS-PSC trial demonstrates that bexotegrast, a dual αvβ6/αvβ1 integrin inhibitor, is well tolerated in PSC patients with liver fibrosis and shows potential to attenuate fibrotic progression, supporting integrin-targeted th

Primary Sclerosing Cholangitis in a 45-Year-Old Male: A Case Report
Gastroenterologycase reportdiagnosis

Primary Sclerosing Cholangitis in a 45-Year-Old Male: A Case Report

By MedXY|Oct 6, 2025

A 45-year-old male presents with cholestatic liver enzyme elevation and pruritus, diagnosed with primary sclerosing cholangitis confirmed by imaging and liver biopsy. Clinical management and prognosis are discussed.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities